775 related articles for article (PubMed ID: 26857781)
1. Uric acid and high-residual platelet reactivity in patients treated with clopidogrel or ticagrelor.
Barbieri L; Verdoia M; Pergolini P; Nardin M; Rolla R; Marino P; Bellomo G; Suryapranata H; De Luca G;
Nutr Metab Cardiovasc Dis; 2016 Apr; 26(4):352-8. PubMed ID: 26857781
[TBL] [Abstract][Full Text] [Related]
2. Platelet reactivity in patients with impaired renal function receiving dual antiplatelet therapy with clopidogrel or ticagrelor.
Barbieri L; Pergolini P; Verdoia M; Rolla R; Nardin M; Marino P; Bellomo G; Suryapranata H; De Luca G;
Vascul Pharmacol; 2016 Apr; 79():11-15. PubMed ID: 26518440
[TBL] [Abstract][Full Text] [Related]
3. Serum uric acid levels during dual antiplatelet therapy with ticagrelor or clopidogrel: Results from a single-centre study.
Nardin M; Verdoia M; Pergolini P; Rolla R; Barbieri L; Schaffer A; Marino P; Bellomo G; Suryapranata H; De Luca G;
Nutr Metab Cardiovasc Dis; 2016 Jul; 26(7):567-574. PubMed ID: 27134063
[TBL] [Abstract][Full Text] [Related]
4. Parathyroid Hormone Levels and High-Residual Platelet Reactivity in Patients Receiving Dual Antiplatelet Therapy With Acetylsalicylic Acid and Clopidogrel or Ticagrelor.
Verdoia M; Pergolini P; Rolla R; Nardin M; Barbieri L; Schaffer A; Bellomo G; Marino P; Suryapranata H; De Luca G;
Cardiovasc Ther; 2016 Aug; 34(4):209-15. PubMed ID: 27086085
[TBL] [Abstract][Full Text] [Related]
5. Vitamin D levels and high-residual platelet reactivity in patients receiving dual antiplatelet therapy with clopidogrel or ticagrelor.
Verdoia M; Pergolini P; Rolla R; Sartori C; Nardin M; Schaffer A; Barbieri L; Daffara V; Marino P; Bellomo G; Suryapranata H; De Luca G;
Platelets; 2016 Sep; 27(6):576-82. PubMed ID: 27540959
[TBL] [Abstract][Full Text] [Related]
6. Mean platelet volume and high-residual platelet reactivity in patients receiving dual antiplatelet therapy with clopidogrel or ticagrelor.
Verdoia M; Pergolini P; Rolla R; Nardin M; Barbieri L; Schaffer A; Bellomo G; Marino P; Suryapranata H; De Luca G
Expert Opin Pharmacother; 2015; 16(12):1739-47. PubMed ID: 26067422
[TBL] [Abstract][Full Text] [Related]
7. Body Mass Index and Platelet Reactivity During Dual Antiplatelet Therapy With Clopidogrel or Ticagrelor.
Nardin M; Verdoia M; Sartori C; Pergolini P; Rolla R; Barbieri L; Schaffer A; Marino P; Bellomo G; Suryapranata H; De Luca G;
J Cardiovasc Pharmacol; 2015 Oct; 66(4):364-70. PubMed ID: 26065844
[TBL] [Abstract][Full Text] [Related]
8. Gender Differences in Platelet Reactivity in Patients Receiving Dual Antiplatelet Therapy.
Verdoia M; Pergolini P; Rolla R; Nardin M; Barbieri L; Daffara V; Marino P; Bellomo G; Suryapranata H; Luca GD;
Cardiovasc Drugs Ther; 2016 Apr; 30(2):143-50. PubMed ID: 26868495
[TBL] [Abstract][Full Text] [Related]
9. Advanced age and high-residual platelet reactivity in patients receiving dual antiplatelet therapy with clopidogrel or ticagrelor.
Verdoia M; Pergolini P; Rolla R; Nardin M; Schaffer A; Barbieri L; Marino P; Bellomo G; Suryapranata H; De Luca G
J Thromb Haemost; 2016 Jan; 14(1):57-64. PubMed ID: 26512550
[TBL] [Abstract][Full Text] [Related]
10. Impact of atorvastatin or rosuvastatin co-administration on platelet reactivity in patients treated with dual antiplatelet therapy.
Verdoia M; Nardin M; Sartori C; Pergolini P; Rolla R; Barbieri L; Marino P; Bellomo G; Suryapranata H; De Luca G;
Atherosclerosis; 2015 Dec; 243(2):389-94. PubMed ID: 26520891
[TBL] [Abstract][Full Text] [Related]
11. Platelet Larger Cell Ratio and High-on Treatment Platelet Reactivity During Dual Antiplatelet Therapy.
Verdoia M; Pergolini P; Rolla R; Nardin M; Barbieri L; Schaffer A; Bellomo G; Marino P; Suryapranata H; De Luca G;
Cardiovasc Drugs Ther; 2015; 29(5):443-50. PubMed ID: 26428927
[TBL] [Abstract][Full Text] [Related]
12. Vitamin D Binding Protein rs7041 polymorphism and high-residual platelet reactivity in patients receiving dual antiplatelet therapy with clopidogrel or ticagrelor.
Verdoia M; Daffara V; Pergolini P; Rolla R; Marino P; Bellomo G; Carriero A; De Luca G;
Vascul Pharmacol; 2017 Aug; 93-95():42-47. PubMed ID: 28433569
[TBL] [Abstract][Full Text] [Related]
13. Prevalence and predictors of high-on treatment platelet reactivity with ticagrelor in ACS patients undergoing stent implantation.
Verdoia M; Sartori C; Pergolini P; Nardin M; Rolla R; Barbieri L; Schaffer A; Marino P; Bellomo G; Suryapranata H; De Luca G;
Vascul Pharmacol; 2016 Feb; 77():48-53. PubMed ID: 25956733
[TBL] [Abstract][Full Text] [Related]
14. Vitamin D levels and platelet reactivity in diabetic patients receiving dual antiplatelet therapy.
Verdoia M; Pergolini P; Nardin M; Rolla R; Negro F; Kedhi E; Suryapranata H; Marcolongo M; Carriero A; De Luca G;
Vascul Pharmacol; 2019 Sep; 120():106564. PubMed ID: 31176855
[TBL] [Abstract][Full Text] [Related]
15. Low hemoglobin predicts high-platelet reactivity and major cardiovascular ischemic events at long-term follow-up among ACS patients receiving dual antiplatelet therapy with ticagrelor.
Verdoia M; Rolla R; Pergolini P; Gioscia R; Nardin M; Negro F; Viglione F; Suryapranata H; Kedhi E; De Luca G;
Catheter Cardiovasc Interv; 2021 Dec; 98(7):1309-1316. PubMed ID: 33527669
[TBL] [Abstract][Full Text] [Related]
16. Ticagrelor versus prasugrel in patients with high on-clopidogrel treatment platelet reactivity after PCI: The ISAR-ADAPT-PF study.
Bernlochner I; Mayer K; Orban M; Morath T; Jaitner J; Rössner L; Gross L; Laugwitz KL; Kastrati A; Sibbing D
Platelets; 2016 Dec; 27(8):796-804. PubMed ID: 27275651
[TBL] [Abstract][Full Text] [Related]
17. Impact of diabetes on immature platelets fraction and its relationship with platelet reactivity in patients receiving dual antiplatelet therapy.
Verdoia M; Pergolini P; Nardin M; Rolla R; Barbieri L; Schaffer A; Marino P; Bellomo G; Suryapranata H; De Luca G
J Thromb Thrombolysis; 2016 Aug; 42(2):245-53. PubMed ID: 26951167
[TBL] [Abstract][Full Text] [Related]
18. Impact of aging on platelet reactivity in diabetic patients receiving dual antiplatelet therapy.
Verdoia M; Pergolini P; Nardin M; Rolla R; Tonon F; Kedhi E; Suryapranata H; Carriero A; De Luca G;
J Thromb Thrombolysis; 2019 Oct; 48(3):413-421. PubMed ID: 31065927
[TBL] [Abstract][Full Text] [Related]
19. Disaggregation Following Agonist-Induced Platelet Activation in Patients on Dual Antiplatelet Therapy.
Wadowski PP; Eichelberger B; Kopp CW; Pultar J; Seidinger D; Koppensteiner R; Lang IM; Panzer S; Gremmel T
J Cardiovasc Transl Res; 2017 Aug; 10(4):359-367. PubMed ID: 28425039
[TBL] [Abstract][Full Text] [Related]
20. Higher neutrophil-to-lymphocyte ratio (NLR) increases the risk of suboptimal platelet inhibition and major cardiovascular ischemic events among ACS patients receiving dual antiplatelet therapy with ticagrelor.
Verdoia M; Nardin M; Gioscia R; Negro F; Marcolongo M; Suryapranata H; Kedhi E; De Luca G;
Vascul Pharmacol; 2020 Sep; 132():106765. PubMed ID: 32681888
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
